Genotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico

Rivas-Estilla, Ana María; Cordero-Pérez, Paula; Trujillo-Murillo, Karina del Carmen; Ramos‐Jiménez, Javier; Chen-López, Carlos Y.; Garza-Rodríguez, María de Lourdes; Ramírez-Gutiérrez, Ángel; Muñoz-Espinosa, Linda E.

doi:10.1016/s1665-2681(19)31870-8

Cited by 22 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The key historical risk factor was blood transfusion. Approximately 64–72% of the infected population contracted HCV from contaminated blood, while 2.5% was from IDU (mostly in the Northern part of the country) (74, 75). The blood transfusion risk factor applied only to the existing prevalent population, since blood screening started in 1993 and 80% coverage was achieved by 1996 (73).…”

Section: Resultsmentioning

confidence: 99%

“…The largest study of 8802 chronic patients reported G1 (70.36%), G2 (21.77%), G3 (7.18%) and G4 (0.3%) (92). Genotype 1b was the most common genotype: 32–41% (75, 91, 92).…”

Section: Resultsmentioning

confidence: 99%

“…There have been a number of studies looking at the genotype distribution (5,74,75,77,81,91,92). The largest study of 8802 chronic patients reported G1 (70.36%), G2 (21.77%), G3 (7.18%) and G4 (0.3%) (92).…”

Section: Genotypementioning

confidence: 99%

See 2 more Smart Citations

Trends and projections of hepatitis C virus epidemiology in Latin America

Kershenobich¹,

Razavi²,

Sánchez-Ávila³

et al. 2011

Liver International

132

View full text Add to dashboard Cite

Background and aim: The purpose of the present investigation is to provide an analysis of previous works on the epidemiology of the hepatitis C virus (HCV) infection from six countries throughout Latin America, to forecast the future HCV prevalence trends in Argentina, Brazil, Mexico and Puerto Rico, and to outline deficiencies in available data, highlighting the need for further research. Methods: Data references were identified through indexed journals and non-indexed sources. Overall, 1080 articles were reviewed and 150 were selected based on their relevance to this work. When multiple data sources were available for a key assumption, a systematic process using multi-objective decision analysis (MODA) was used to select the most appropriate sources. When data were missing, analogues were used. Data from other countries with similar risk factors and/or population compositions were used as a proxy to help predict the future trends in prevalence. Results: The review indicates that the dominant genotype is type 1. HCV prevalence in the analysed countries ranges from 1 to 2.3%. The Latin American countries have been very proactive in screening their blood supplies, thus minimizing the risk of transmission through transfusion. This suggests that other risk factors are set to play a major role in continued new infections. The number of diagnosed and treated patients is low, thereby increasing the burden of complications such as liver cirrhosis or hepatocellular carcinoma. The HCV prevalence, according to our modelling is steady or increasing and the number of infected individuals will increase. Conclusions: The results herein reported should provide a foundation for informed planning efforts to tackle hepatitis.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The largest study of 8802 chronic patients reported G1 (70.36%), G2 (21.77%), G3 (7.18%) and G4 (0.3%) (92). Genotype 1b was the most common genotype: 32–41% (75, 91, 92).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Trends and projections of hepatitis C virus epidemiology in Latin America

Kershenobich¹,

Razavi²,

Sánchez-Ávila³

et al. 2011

Liver International

132

View full text Add to dashboard Cite

show abstract

“…In Mexico, an estimated 1 million persons are infected [2, 3] with predominantly genotype 1 hepatitis C virus (HCV) [4-6]. Standard therapy for hepatitis C infection is pegylated interferon and ribavirin [7].…”

Section: Introductionmentioning

confidence: 99%

A Randomized Controlled Trial of Double Versus Triple Therapy with Amantadine for Genotype 1 Chronic Hepatitis C in Latino Patients

et al. 2009

View full text Add to dashboard Cite

Background With only a third of Latinos achieving sustained virologic response (SVR), there is a need for enhanced HCV treatment. Amantadine has been proposed to improve response rates in addition to standard therapy with peginterferon a and ribavirin. Our objective is to evaluate whether triple therapy with amantadine improves SVR rates in this special population. Method Treatment-naíe Latino subjects with HCV genotype 1 infection were randomized to receive peginterferon [alpha]-2a plus weight-based ribavirin for 48 weeks (double therapy) or the same regimen plus amantadine 200 mg daily (triple therapy). The primary endpoint was SVR. Predictors of liver fibrosis using APRI and Forns indices were also evaluated. Results We enrolled 124 patients with chronic hepatitis C genotype 1. Sixty-three received conventional therapy and 61 patients had triple therapy with amantadine. SVR at week 72 was achieved in 25 patients (39.7%) vs. 26 patients (42.6%) in the double and triple regimen, respectively (p = 0.561).After multivariate analysis, advanced fibrosis, obesity, and low pretreatment ALT levels were associated with non-response in both groups (p = 0.0234, p = 0.0012, p = 0.0249, respectively). APRI values delimited an area under the ROC curve (AUROC) of 0.724 and Forns index with AUROC of 0.733. There was no difference between both indices in predicting significant fibrosis (Knodell index: F3-F4). Conclusion Our study demonstrates that the addition of amantadine to standard treatment of chronic HCV does not improve SVR rates in Latino patients with genotype 1. Further research to improve response rates in this special population is needed.

show abstract

“…Similar to our findings, Marcial et al reported the association between HCV subtype 1b and old age in the HCV/HIV-coinfected group. 27 Studies in the Caribbean Islands 27 and in the Continental region of the Americas 37,38 report the existence of the six genotypes of HCV with the predominance of genotype 1 (subtypes a and b) with some countries having a geographic distribution pattern of different HCV genotypes. The molecular epidemiology and natural history of HCV shows a wide range of genotypes circulating among the main risk groups for HCV infection and in populations with no apparent risk for HCV infection around the world.…”

Section: Discussionmentioning

confidence: 99%

HCV genotype determination in monoinfected and HIV co-infected patients in Cuba

Lay

Villalba

Corredor

et al. 2012

Transactions of the Royal Society of Tropical Medicine and Hygi

View full text Add to dashboard Cite

With the aim to characterize the HCV genotype distribution in Cuba, sera were collected from two subgroups: HCV-monoinfected and HCV/HIV co-infected patients. A combination of reverse transcription-PCR using genotype-specific primers, restriction fragment length polymorphism and sequencing was used to determine the genotype of 84 samples. Seventy-nine (94%) showed single infections (10 [12%] were genotype 1a and 69 [82%] genotype 1b) and 5 (6%) samples corresponded to mixed infections (2 [2%] with genotypes 1a/3a and 1 sample [1%] each with 1b/3a, 1b/4a and 1a/1b/3a). HCV/HIV co-infected subjects had a higher frequency of mixed infections (p=0.08), infection with genotype 3a (p=0.18) and for the first time genotype 4a was found. There was no association of any demographic characteristics with any specific genotype although HCV/HIV co-infected patients showed a tendency to have mixed genotypes in those older than 45 years of age (p=0.11). Phylogenetic analysis showed that HCV isolates clustered with subtypes 1b (n=15, maximal genetic distance 2.51%) and 1a (n=2, maximal genetic distance 0.35%). This report presents the prevalence of HCV genotypes in monoinfected and HIV co-infected patients, mixed HCV infections in HCV/HIV co-infected men who have sex with men with high-risk sexual practices and for the first time identifies that the uncommon genotype 4a can be present in a patient co-infected with HIV.

show abstract

Genotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico

Cited by 22 publications

References 12 publications

Trends and projections of hepatitis C virus epidemiology in Latin America

Trends and projections of hepatitis C virus epidemiology in Latin America

A Randomized Controlled Trial of Double Versus Triple Therapy with Amantadine for Genotype 1 Chronic Hepatitis C in Latino Patients

HCV genotype determination in monoinfected and HIV co-infected patients in Cuba

Contact Info

Product

Resources

About